WAYNESBORO HOSPITAL
1. Target Overview & Investment Thesis
WAYNESBORO HOSPITAL is a 57-bed suburban community hospital in FRANKLIN, PA with $84.2M in net patient revenue and a 15.1% operating margin. The hospital serves a payer mix of 47.6% Medicare, 1.9% Medicaid, and 50.4% commercial.
Thesis: Turnaround. Our ML models identify $6.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 15.1% to 22.5% (+736bps).
| Net Revenue HCRIS | $84.2M |
| Current EBITDA COMPUTED | $12.7M |
| Operating Margin COMPUTED | 15.1% |
| Occupancy HCRIS | 34.2% |
| Revenue / Bed COMPUTED | $1.5M |
| Net-to-Gross HCRIS | 30.8% |
| Distress Probability ML | 51.6% |
2. Market Context & Competitive Position
PA has 225 Medicare-certified hospitals with a median operating margin of -4.4%. The target's margin of 15.1% places it above the state median. Among 85 size-comparable peers (28-114 beds), the median margin is -0.1%. The target performs in line with or above peers.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (28-114), prioritizing same-state peers. 85 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| WAYNESBORO HOSPITAL (Target) | PA | 57 | $84.2M | 15.1% |
| THE GETTYSBURG HOSPITAL | PA | 76 | $341.8M | 18.4% |
| AMERICAN ONCOLOGIC HOSPIAL | PA | 100 | $229.8M | -11.1% |
| ST. LUKES HOSPITAL - MONROE CA | PA | 98 | $221.8M | 7.8% |
| GEISINGER LEWISTOWN HOSPITAL | PA | 107 | $210.8M | 11.2% |
| UPMC HANOVER | PA | 73 | $200.8M | 18.2% |
| MEMORIAL HOSPITAL | PA | 80 | $184.5M | 13.1% |
| UPMC CARLISLE | PA | 72 | $165.0M | 19.5% |
| UPMC HORIZON HOSPITAL | PA | 99 | $156.4M | -16.5% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $6.2M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $1.8M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $1.7M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $1.7M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $1.0M | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $54K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $12.7M |
| + RCM Uplift | +$6.2M |
| Pro Forma EBITDA | $18.9M |
| Current Margin | 15.1% |
| Pro Forma Margin | 22.5% |
| WC Released (1x) | $3.2M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $19.6M | $145.8M | 7.46x | 49.5% |
| Base (11x exit) | 10.0x | 11.0x | $19.6M | $166.8M | 8.53x | 53.5% |
| Bull Case | 9.0x | 11.0x | $17.6M | $193.6M | 11.00x | 61.5% |
| Bull (12x exit) | 9.0x | 12.0x | $17.6M | $216.4M | 12.29x | 65.2% |
| Bear Case | 11.0x | 10.0x | $21.5M | $108.5M | 5.04x | 38.2% |
| Bear (11x exit) | 11.0x | 11.0x | $21.5M | $126.3M | 5.87x | 42.5% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| Medium | Low occupancy | At 34.2%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case |
| High | Elevated distress probability | Model estimates 51.6% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 85 hospitals with 28-114 beds
- Same-state prioritization (n=86)
- Comp margins: P25=-18.2% / P50=-0.1% / P75=8.9%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.